Xenon Seven

Xenon Seven

Director, Medical Affairs (Epilepsy)

Boston · Director

Sponsorship not specifiedDetected 62 days ago
RESTProduct ManagementClinical TrialsPatient CarePharmacovigilanceResearchCommunicationCollaborationCritical Thinking

About the role

  • To be successful in this role, you are a scientific or clinical professional with strong therapeutic area knowledge, a passion for evidence-based medicine, and a collaborative mindset.
  • This position reports to the Executive Director, Medical Affairs and will work collaboratively with Clinical Development, Regulatory, Commercial, Market Access, and other internal stakeholders.
  • This position will be based out of Boston, MA, USA in our Needham office.

Requirements

  • Experience reviewing scientific publications and participating in promotional material review
  • Must be self-motivated and able to work autonomously
  • PhD, PharmD, MD, or other recognized doctorate level education with supporting applicable health science background
  • 7+ years of experience in progressive Medical Affairs Management positions experience in the pharmaceutical or biotech industry is preferred
  • Candidates with a strong medical or scientific background preferably in neurology or psychiatry
  • Experience working cross functionally within Medical Affairs, Clinical Development, or related functions
  • Prior involvement in Phase IV, investigator initiated, or collaborative research studies
  • Neuroscience experience preferred; epilepsy experience a plus
  • Strong scientific acumen, critical thinking skills, and attention to detail
  • Ability to manage multiple projects and collaborate effectively in a fast-paced, matrix environment
  • Excellent writing, communication, and presentation skills
  • Willingness to travel up to 25% domestically and internationally

Nice to have

  • Neuroscience experience preferred
  • epilepsy experience a plus

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Benefits

  • Medical Strategy & Execution
  • Support the development and execution of medical affairs plans for Xenon's epilepsy program in alignment with overall medical, clinical development, and commercialization strategies
  • Maintain strong understanding of product data, disease state, and evolving clinical landscape to support internal discussions and medical decision making
  • Contribute to insight gathering activities and evidence planning to inform medical strategy and launch preparation
  • Serve as a key Medical Affairs partner for epilepsy related activities, collaborating with Commercial/Marketing, Market Access, Regulatory, Legal/Compliance, Pharmacovigilance, and other functions as appropriate
  • Review promotional and non promotional materials as a Medical Affairs reviewer to ensure scientific accuracy and compliance with internal and external standards
  • Support scientific engagement with healthcare professionals, key opinion leaders, and patient advocacy organizations to gather insights and support medical strategy
  • Represent Medical Affairs in scientific discussions to advance understanding of Xenon's research and commitment to patients

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.